دورية أكاديمية
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudina/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients.
| العنوان: | Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudina/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients. |
|---|---|
| المؤلفون: | F. Olearo, H. NNguyen, F. Bonnet, S. Yerly, G. Wander, M. Stoexkle, M. Cavassini, A. Scherrer, D. Costagliola, P. Schmid, H. F. Gunthard, E. Bernasconi, J. Boeni, A. D’Arminio Monforte, M. Zazzi, B. Rossetti, D. Neau, P. Bellecave, B. Rijnders, P. Reiss, F. Wit, R. Kouyos, A. Calmy, we acknowledge member of the ICONA Group, G. Nunnari, G. F. Pellicanò |
| المساهمون: | Olearo, F., NNguyen, H., Bonnet, F., Yerly, S., Wander, G., Stoexkle, M., Cavassini, M., Scherrer, A., Costagliola, D., Schmid, P., Gunthard, H. F., Bernasconi, E., Boeni, J., D’Arminio Monforte, A., Zazzi, M., Rossetti, B., Neau, D., Bellecave, P., Rijnders, B., Reiss, P., Wit, F., Kouyos, R., Calmy, A., acknowledge member of the ICONA Group, We, Nunnari, G., Pellicanò, G. F. |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2019 |
| المجموعة: | Università degli Studi di Messina: IRIS |
| مصطلحات موضوعية: | ABC/3TC/DTG, virological failure, M184V/I, treatment-experienced patients |
| الوصف: | Background The impact of the M184V/I mutation on the virological failure (VF) rate in HIV-positive patients with suppressed viremia switching to an abacavir/lamivudine/dolutegravir regimen has been poorly evaluated. Methods Observational study from five European HIV cohorts among treatment-experienced adults with ≤50 copies/mL of HIV-1 RNA who switched to abacavir/lamivudine/dolutegravir. Primary outcome was the time to first VF (two consecutive HIV-1 RNA >50 copies/mL or single HIV-1 RNA >50 copies/mL accompanied by change in ART). We also analyzed a composite outcome considering the presence of VF and/or virological blips. We report also the results of an inverse probability weighting (IPW) analysis on a restricted population with a prior history of VF on any ART regimen to calculate statistics standardized to the disparate sampling population. Results We included 1626 patients (median follow-up, 288.5 days [IQR, 154-441]). Patients with a genotypically documented M184V/I mutation (n=137) had a lower CD4 nadir and a longer history of antiviral treatment. The incidence of VF was 29.8 (11.2-79.4) per 1000 person-years in those with a previously documented M184V/I, and 13.6 (8.4-21.8) in patients without documented M184V/I. Propensity score weighting in a restricted population (n=580) showed that M184V/I was not associated with VF or the composite endpoint (HR 1.27 [95% CI 0.35-4.59]; HR 1.66 [95% CI 0.81–3.43], respectively). Conclusions In ART-experienced patients switching to an abacavir/lamivudine/dolutegravir treatment, we observed few VFs and found no evidence for an impact of previously-acquired M184V/I mutation on this outcome. Additional analyses are required to demonstrate whether these findings will remain robust during a longer follow-up. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31660328; info:eu-repo/semantics/altIdentifier/wos/WOS:000510164000004; volume:6; issue:10; firstpage:1; lastpage:42; numberofpages:42; journal:OPEN FORUM INFECTIOUS DISEASES; http://hdl.handle.net/11570/3143653Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85073566350 |
| DOI: | 10.1093/ofid/ofz330 |
| DOI: | 10.1093/ofid/ofz330/5532016 |
| الإتاحة: | https://doi.org/10.1093/ofid/ofz330Test http://hdl.handle.net/11570/3143653Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.5102375D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ofid/ofz330 |
|---|